Innoviva, Inc. (INVA)
Nasdaq: INVA · Pharmaceutical Preparations · Burlingame, CA · filing with the SEC since 2000
Grade6.2
◀ Past 6.4● Present 6.5▶ Future 5.7
Who owns Innoviva, Inc.
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 15.4% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
8
report now, of 27 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 14% in Apr 28, 2025
Dimensional Fund Advisors LP
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Renaissance Technologies LLC
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.01 per share · 7.56% in Aug 13, 2025
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Sarissa Capital Management LP
SCHEDULE 13D/A · filed Mar 17, 2025 · Common Stock, par value $0.01 per share · reported falling below 5%, from 8.4% in Mar 7, 2025
Franklin Resources, Inc.
SCHEDULE 13G/A · filed Aug 5, 2025 · Common Stock, par value $0.01 per share · reported falling below 5%, from 7.1% in Jan 27, 2025
Bank of Nova Scotia
SCHEDULE 13G/A · filed Oct 8, 2025 · Common Stock · reported falling below 5%, from 5.55% in Sep 3, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
Westfield Capital Management Company, L.P.
SCHEDULE 13G/A · filed Feb 11, 2025 · Common Stock · reported falling below 5%
What INVA reports owning in othersstakes of 5% or more, and other ties
Armata Pharmaceuticals, Inc. ARMP
SCHEDULE 13D/A · filed May 13, 2026 · Common Stock, $0.01 par value
Other ties the annual report names
Armata Pharmaceuticals Inc
An entity · consolidated entity · owns, named in the 10-K filed Feb 25, 2026
Entasis Therapeutics Holdings Inc
An entity · consolidated entity · owns, named in the 10-K filed Feb 25, 2026
Imaginab
An entity · consolidated entity · owns, named in the 10-K filed Feb 25, 2026
Isp Fund Lp
An entity · consolidated entity · owns, named in the 10-K filed Feb 25, 2026
Syndeio Biosciences
An entity · consolidated entity · owns, named in the 10-K filed Feb 25, 2026
La Jolla Pharmaceutical Company
A company bought · acquisition · Aug 2022 · owns, named in the 10-K filed Feb 25, 2026
Lyndra
A company bought · asset acquisition · owns, named in the 10-K filed Feb 25, 2026
17 subsidiaries in 2 countries, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.